Highlights Alkem Laboratories Limited

Equities

ALKEM

INE540L01014

Pharmaceuticals

Market Closed - NSE India S.E. Other stock markets 06:49:44 2025-12-12 am EST			5-day change	1st Jan Change
5,631.00 ^INR	+0.09%		-0.78%	-0.05%

Dec. 10	Alkem Laboratories Gets Three Major Observations from Malta Medicines Authority for Daman, India Unit	MT
Nov. 20	Alkem Laboratories Limited Launches Probiotic "DSS", the Original De Simone Formulation, in India for Gut Health Management	CI

Highlights

Alkem Laboratories Gets Three Major Observations from Malta Medicines Authority for Daman, India Unit	Dec. 10	MT
Alkem Laboratories Limited Launches Probiotic "DSS", the Original De Simone Formulation, in India for Gut Health Management	Nov. 20	CI
Alkem Laboratories Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2025	Nov. 13	CI
Alkem Laboratories' Consolidated Profit Rises in Fiscal Q2	Nov. 13	MT
Alkem Labs sept-quarter consol net profit 7.65 billion rupees	Nov. 13	RE
Alkem Laboratories Arm Ties Up With Indian Institute of Technology Bombay for New Research Center	Nov. 03	MT
Alkem Laboratories Limited Launches Pertuzumab Biosimilar in India for Treatment of HER2-Positive Breast Cancer	Sep. 22	CI
Alkem Laboratories Limited Launches Olesoft Trucera, an Advanced Ceramide-Boosting Moisturizing Lion for Skin Barrier Repair	Aug. 19	CI
Alkem Laboratories Launches New Moisturizing Lotion	Aug. 19	MT
INDIA STOCKS-India's stock benchmarks inch lower ahead of inflation data	Aug. 12	RE
Alkem Laboratories' Consolidated Profit Rises in Fiscal Q1; Shares Up 6%	Aug. 12	MT
Alkem Laboratories Limited Reports Earnings Results for the First Quarter Ended June 30, 2025	Aug. 12	CI
Alkem Laboratories Limited Agrees to Incorporate Subsidiary Company in the Kingdom of Saudi Arabia	Aug. 12	CI
Rubicon Research Limited completed the acquisition of Manufacturing facility in Pithampur, Madhya Pradesh from Alkem Laboratories Limited.	Jun. 22	CI
Alkem Laboratories Limited Recommends Final Dividend for Financial Year Ended 31 March, 2025, Payable on and from 29 August, 2025	May. 29	CI
Alkem Laboratories Limited Reports Earnings Results for the Full Year Ended March 31, 2025	May. 29	CI
Alkem Laboratories Acquires 100% Stake In Adroit Biomed	Apr. 23	RE
Alkem Laboratories Limited completed the acquisition of Adroit Biomed Ltd.	Apr. 22	CI
Alkem Laboratories Unit Executes Agreement to Acquire 100% Stake in Bombay Ortho	Mar. 17	MT
Alkem Laboratories Completes USFDA BIMO Inspection with No Observations	Mar. 13	MT
Alkem Laboratories Launches Generic Version of Empagliflozin in India	Mar. 12	MT
Alkem Laboratories Limited Launches Generic Empagliflozin	Mar. 12	CI
Alkem Laboratories To Acquire 100% Stake In Adroit Biomed	Feb. 07	RE
Alkem Laboratories Limited Approves Interim Dividend for 2024- 2025, Payable on and from 28 February, 2025	Feb. 07	CI
Alkem Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2024	Feb. 07	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Alkem Laboratories Limited

Equities

ALKEM

INE540L01014

Pharmaceuticals

Highlights

Filters